All Articles
By Wayne Kuznar
Zanubrutinib, a highly specific and irreversible next-generation Bruton’s tyrosine kinase (BTK) inhibitor, exhibited excellent activity in a single-arm, open-label multicenter phase 2 clinical trial of patients with relapsed or refractory mantle-cell lymphoma (MCL). Early study results were reported at ASH 2018. Read More ›
By Chase Doyle
The results of a phase 2 clinical trial presented at ASH 2018 suggest that early therapeutic intervention is beneficial in patients with high-risk smoldering multiple myeloma. Read More ›
Approvals for new delivery methods for Herceptin and Cinvanti, and a new indication for Lonsurf close out the month of February in the FDA’s oncology-related activity. Read More ›
In This Article:
- FDA approves Lonsurf (trifluridine/tipiracil) for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma
- Additional Method of Administration Approved for Cinvanti in Chemotherapy-Induced Nausea and Vomiting
- FDA Grants Approval to New Formulation of Herceptin
By Chase Doyle
Real-world data highlight the significant clinical and economic burden associated with venous thromboembolism (VTE) in patients with cancer. The data come from a study of 12,785 patients hospitalized with acute illnesses, of which 2002 patients had cancer. Read More ›
By Wayne Kuznar
A novel tumor metabolism-altering oral regimen that combines a tyrosine derivative (D,L-alpha-metyrosine) with 3 repurposed agents (sirolimus, phenytoin, and methoxsalen) has demonstrated promising activity in patients with previously treated metastatic pancreatic cancer. Read More ›
By Chase Doyle
An analysis of real-world administrative claims data in patients with chronic lymphocytic leukemia (CLL) has highlighted the need for treatments that result in fewer adverse events, according to data presented at ASH 2018. Read More ›